Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5TQ2O)

• Drug Name: Galangin Drug Info
• Synonyms: Galangin; 548-83-4; Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; UNII-142FWE6ECS; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; EINECS 208-960-4; NSC407229; FLAVONE, 3,5,7-TRIHYDROXY-; NSC 407229; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; BRN 0272179; 142FWE6ECS; 3,5,7-trihydroxy-2-phenylchromen-4-one; CHEBI:5262; CHEMBL309490; VCCRNZQBSJXYJD-UHFFFAOYSA-N; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5281616
  ChEBI ID: CHEBI:5262
  CAS Number: CAS 548-83-4
  TTD Drug ID: DM5TQ2O

Molecule-Related Drug Atlas

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[5]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[6]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[7]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[8]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[9]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[10]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[11]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[8]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[8]
Methylthioadenosine	DMC8J6F	Multiple sclerosis	8A40	Terminated	[12]

Drug(s) Targeting Adenosine A2a receptor (ADORA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Orthostatic hypotension	BA21	Approved	[13]
Istradefylline	DM20VSK	Parkinson disease	8A00.0	Approved	[14]
Regadenoson	DM76VHG	Radionuclide imaging	N.A.	Approved	[15]
Tozadenant	DMATC14	Parkinson disease	8A00.0	Phase 3	[16]
Binodenoson	DMVHF8G	Hypertension	BA00-BA04	Phase 3	[17]
Apadenoson	DMD8QTC	Coronary artery disease	BA80	Phase 3	[18]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[6]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[19]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[20]
BIIB014	DMH7RJ1	Parkinson disease	8A00.0	Phase 2	[21]

Drug(s) Targeting Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PINOCEMBRIN	DM96VWD	N. A.	N. A.	Phase 2	[4]
Naringenin	DMHAZLM	N. A.	N. A.	Phase 1	[4]
Chrysin	DM7V2LG	Discovery agent	N.A.	Investigative	[4]
Apigenin	DMI3491	Discovery agent	N.A.	Investigative	[4]
Kaempferol	DMHEMUB	Discovery agent	N.A.	Investigative	[4]
ISORHAMNETIN	DMQ4Z6E	Discovery agent	N.A.	Investigative	[4]
Acacetin	DMQOB0X	Discovery agent	N.A.	Investigative	[4]
TRISMETHOXYRESVERATROL	DM6USPC	Discovery agent	N.A.	Investigative	[22]
CHRYSOERIOL	DM96ECL	Discovery agent	N.A.	Investigative	[4]
DIOSMETIN	DM4KXIM	Discovery agent	N.A.	Investigative	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A2a receptor (ADORA2A)	TTM2AOE	AA2AR_HUMAN	Inhibitor	[2]
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[3]
Cytochrome P450 1B1 (CYP1B1)	TTI84H7	CP1B1_HUMAN	Inhibitor	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 410).
• [2] Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem. 1997 Aug 1;40(16):2588-95.
• [3] Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996 Feb 2;39(3):781-8.
• [4] Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
• [5] A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
• [6] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [7] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [8] 2011 Pipeline of Can-Fite BioPharm.
• [9] Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
• [10] 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
• [11] Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
• [12] Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55.
• [13] Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [16] Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
• [17] Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
• [19] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [20] Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
• [21] Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
• [22] Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.